# Genomic Responses of Human Immune and Non-Immune Cells to Glucocorticoids

> **NCT02798523** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 33 (actual)

## Conditions studied

- Normal Physiology

## Interventions

- **DRUG:** Methylprednisolone sodium succinate(Solu-Medrol)
- **DRUG:** Topical methylprednisolone (Advantan emulsion 0 /1%)

## Key facts

- **NCT ID:** NCT02798523
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-24
- **Primary completion:** 2022-05-31
- **Final completion:** 2022-11-14
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2023-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02798523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02798523, "Genomic Responses of Human Immune and Non-Immune Cells to Glucocorticoids". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02798523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*